In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients

被引:11
|
作者
Pust, Gesa E. A. [1 ,2 ]
Poettgen, Jana [1 ]
Randerath, Jennifer [2 ,3 ]
Lau, Stephanie [1 ]
Heesen, Christoph [1 ,4 ]
Gold, Stefan M. [1 ,5 ,6 ]
Penner, Iris-Katharina [7 ,8 ]
机构
[1] Univ Klinikum Hamburg Eppendorf, Inst Neuroimmunol & Multiple Sklerose INIMS, ZMNH, Hamburg, Germany
[2] Univ Konstanz, Dept Psychol, Constance, Germany
[3] Univ Konstanz, Schmieder Fdn Sci & Res, Lurija Inst Rehabil & Hlth Sci, Allensbach, Germany
[4] Univ Klinikum Hamburg Eppendorf UKE, Klin & Poliklin Neurol, Hamburg, Germany
[5] Charite Univ Med Berlin, Klin Psychiat & Psychotherapie, Campus Benjamin Franklin, Berlin, Germany
[6] Charite Univ Med Berlin, Med Klin MS Psychosomat, Campus Benjamin Franklin, Berlin, Germany
[7] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany
[8] COGITO Ctr Appl Neurocognit & Neuropsychol Res, Dusseldorf, Germany
关键词
Fatigue; Assessment; Validation; Multiple sclerosis;
D O I
10.1007/s00415-019-09311-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fatigue is among the most disabling symptoms in patients with multiple sclerosis (PwMS). The common distinction between cognitive and motor fatigue is typically incorporated in self-rating instruments, such as the Chalder Fatigue Questionnaire (CFQ), the Fatigue Scale for Motor and Cognitive Functions (FSMC) or the Modified Fatigue Impact Scale (MFIS). The present study investigated the factor structure of the CFQ, the FSMC and the MFIS utilizing exploratory (EFA) and confirmatory factor analysis (CFA) as well as exploratory structural equation modeling (ESEM). Data of 1.403 PwMS were analyzed, utilizing four samples. The first sample (N=605) was assessed online and split into two stratified halves to perform EFA, CFA, and ESEM on the CFQ and FSMC. The second sample (N=293) was another online sample. It served to calculate CFA and ESEM on the CFQ and FSMC. The third sample was gathered in a clinical setting (N=196) and analyzed by applying CFA and ESEM to the FSMC. The fourth sample (N=309) was assessed in a clinical setting and allowed to run a CFA and ESEM on the MFIS. Proposed factor structures of all questionnaires were largely confirmed in EFA. However, none of the calculated CFAs and ESEMs could verify the proposed factor structures of the three measures, even with oblique rotation techniques. The findings might have implications for future research into the pathophysiological basis of MS-related fatigue and could affect the suitability of such measures as outcomes for treatment trials, presumably targeting specific sub-components of fatigue.
引用
收藏
页码:1663 / 1673
页数:11
相关论文
共 49 条
  • [31] Ocrelizumab in patients with early-stage RRMS - results from the phase IIIb ENSEMBLE trial and the matched real-world NTD MS registry cohort
    Hartung, H. -P.
    Holmoy, T.
    Wuerfel, J.
    Heer, Y.
    Braune, S.
    Bergmann, A.
    Zuercher, M.
    Liu, C.
    Kuenzel, T.
    Moore, S.
    Vollmer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 673 - 674
  • [32] Cognitive function alone is a poor predictor of health-related quality of life in employed patients with MS: results from a cross-sectional study
    Giovannetti, Ambra Mara
    Schiavolin, Silvia
    Brenna, Greta
    Brambilla, Laura
    Confalonieri, Paolo
    Cortese, Francesca
    Covelli, Venusia
    Frangiamore, Rita
    Leonardi, Matilde
    Mantegazza, Renato
    Moscatelli, Marco
    Ponzio, Michela
    Clerici, Valentina Torri
    Zaratin, Paola
    Raggi, Alberto
    CLINICAL NEUROPSYCHOLOGIST, 2016, 30 (02) : 201 - 215
  • [33] Assessing the effects of IFNβ-1a on health-related quality of life in secondary-progressive MS patients:: Results from the IMPACT study
    Miller, DM
    Cohen, JA
    Tsao, EC
    Kooijmans, MF
    Simonian, NA
    NEUROLOGY, 2002, 58 (07) : A456 - A456
  • [34] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
    Wu, Junwei
    Zhou, Chenfei
    Yan, Jun
    Han, Zhengxiang
    Wang, Chun
    Qin, Zhiquan
    Jiang, Jinling
    Wang, Chunbing
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Mao, Yong
    Wei, Xiaowei
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 653 - 653
  • [35] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C
    Wu, J.
    Zhou, C.
    Yan, J.
    Han, Z.
    Wang, C.
    Qin, Z.
    Jiang, J.
    Wang, C.
    Tang, X.
    Zhu, L.
    Chen, J.
    Mao, Y.
    Wei, X.
    Shangguan, C.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1533 - S1533
  • [36] Safety and Efficacy of RP1+Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial
    Niu, J.
    Milhem, M.
    Vanderwalde, A. M.
    Chmielowski, B.
    Beasley, G.
    Samson, A.
    Sacco, J. J.
    Bowles, T.
    Jew, T.
    He, S.
    Raza, S.
    Harrington, K.
    Middleton, M. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E8 - E9
  • [37] Analysis of brain functional connectivity network in MS patients constructed by modular structure of sparse weights from cognitive task-related fMRI
    Ashtiani, Seyedeh Naghmeh Miri
    Behnam, Hamid
    Daliri, Mohammad Reza
    Hossein-Zadeh, Gholam-Ali
    Mehrpour, Masoud
    AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE, 2019, 42 (04) : 921 - 938
  • [38] Analysis of brain functional connectivity network in MS patients constructed by modular structure of sparse weights from cognitive task-related fMRI
    Seyedeh Naghmeh Miri Ashtiani
    Hamid Behnam
    Mohammad Reza Daliri
    Gholam-Ali Hossein-Zadeh
    Masoud Mehrpour
    Australasian Physical & Engineering Sciences in Medicine, 2019, 42 : 921 - 938
  • [39] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
    Zhou, C.
    Zhang, J.
    Wu, J.
    Jiang, J.
    Zhu, L.
    Yan, J.
    Wang, C.
    Mao, Y.
    Tang, X.
    Chen, J.
    Wang, C.
    Qin, Z.
    Han, Z.
    Wei, X.
    Shangguan, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S50 - S51
  • [40] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001)
    Zhou, Chenfei
    Wu, Junwei
    Yan, Jun
    Wang, Chun
    Mao, Yong
    Tang, Xinyu
    Zhu, Lingjun
    Chen, Jun
    Wang, Chunbing
    Qin, Zhiquan
    Han, Zhengxiang
    Shangguan, Chengfang
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)